Unapproved Topical Pain-Relief Products Pose Danger to Consumers: FDA Warning Targets Excessive Lidocaine Content

FDA cautions that widely used pain-relief creams could present serious health hazards

Recently, the U.S. Food and Drug Administration (FDA) issued a warning to six companies for selling unapproved and misbranded over-the-counter topical pain-relief products that contain higher-than-allowed concentrations of lidocaine, a local anesthetic. Jill Furman, director of the Office of Compliance in the FDA’s Center for Drug Evaluation and Research, emphasized the risks associated with these products, stating that they should not be on the market due to their potential harm to consumers.

The problem with these products is their excessive lidocaine content, which can lead to serious side effects such as irregular heartbeat, seizures, and breathing difficulties when used on large areas of skin or irritated skin. To prevent adverse effects, the FDA recommends avoiding products containing more than 4% lidocaine, refraining from usage on large areas of skin, and avoiding wrapping the product with dressings or plastic wraps. Some of the products cited by the FDA in their warning include TKTX Numb Maximum Strength Pain Reliever, NumbSkin Lidocaine Numbing Creams, and Signature Tattoo Numbing Cream.

It is essential for individuals who regularly undergo cosmetic procedures such as microdermabrasion treatments, laser hair removal, tattoos, or piercings to take note of this warning from the FDA. By following these guidelines and using only approved products that comply with safety regulations set by the FDA, individuals can protect their health and well-being while undergoing these procedures.

Leave a Reply